Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

The London Metal Exchange is in its final stages to approve Hong Kong as the main warehousing network for its metals.

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...